Resource Summary Report

Generated by FDI Lab - SciCrunch.org on May 6, 2025

RUNX1 / AML1 antibody - ChIP Grade

RRID:AB_2184205
Type: Antibody

Proper Citation

(Abcam Cat# ab23980, RRID:AB_2184205)

Antibody Information

URL: http://antibodyregistry.org/AB_2184205

Proper Citation: (Abcam Cat# ab23980, RRID:AB_2184205)

Target Antigen: RUNX1

Host Organism: rabbit

Clonality: polyclonal

Comments: validation status unknown, seller recommendations provided in 2012:western blot, immunoprecipitation

Antibody Name: RUNX1 / AML1 antibody - ChIP Grade

Description: This polyclonal targets RUNX1

Target Organism: human

Antibody ID: AB_2184205

Vendor: Abcam

Catalog Number: ab23980

Record Creation Time: 20231110T045925+0000

Record Last Update: 20241115T041542+0000

Ratings and Alerts

No rating or validation information has been found for RUNX1 / AML1 antibody - ChIP Grade.

No alerts have been found for RUNX1 / AML1 antibody - ChIP Grade.

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 20 mentions in open access literature.

Listed below are recent publications. The full list is available at FDI Lab - SciCrunch.org.

Coleman DJL, et al. (2024) Pharmacological inhibition of RAS overcomes FLT3 inhibitor resistance in FLT3-ITD+ AML through AP-1 and RUNX1. iScience, 27(4), 109576.

Lopes-Paciencia S, et al. (2024) A senescence restriction point acting on chromatin integrates oncogenic signals. Cell reports, 43(4), 114044.

Xu L, et al. (2023) Gramine protects against pressure overload-induced pathological cardiac hypertrophy through Runx1-TGFBR1 signaling. Phytomedicine : international journal of phytotherapy and phytopharmacology, 114, 154779.

Chambers C, et al. (2023) SWI/SNF Blockade Disrupts PU.1-Directed Enhancer Programs in Normal Hematopoietic Cells and Acute Myeloid Leukemia. Cancer research, 83(7), 983.

Nicosia L, et al. (2023) Therapeutic targeting of EP300/CBP by bromodomain inhibition in hematologic malignancies. Cancer cell, 41(12), 2136.

Hattori EY, et al. (2022) A RUNX-targeted gene switch-off approach modulates the BIRC5/PIF1-p21 pathway and reduces glioblastoma growth in mice. Communications biology, 5(1), 939.

Wosczyna MN, et al. (2021) Targeting microRNA-mediated gene repression limits adipogenic conversion of skeletal muscle mesenchymal stromal cells. Cell stem cell, 28(7), 1323.

Heib T, et al. (2021) RhoA/Cdc42 signaling drives cytoplasmic maturation but not endomitosis in megakaryocytes. Cell reports, 35(6), 109102.

Potluri S, et al. (2021) Isoform-specific and signaling-dependent propagation of acute myeloid leukemia by Wilms tumor 1. Cell reports, 35(3), 109010.

Simeoni F, et al. (2021) Enhancer recruitment of transcription repressors RUNX1 and TLE3 by mis-expressed FOXC1 blocks differentiation in acute myeloid leukemia. Cell reports,

36(12), 109725.

Huang Z, et al. (2021) The corepressors GPS2 and SMRT control enhancer and silencer remodeling via eRNA transcription during inflammatory activation of macrophages. Molecular cell, 81(5), 953.

Wesely J, et al. (2020) Acute Myeloid Leukemia iPSCs Reveal a Role for RUNX1 in the Maintenance of Human Leukemia Stem Cells. Cell reports, 31(9), 107688.

Nafria M, et al. (2020) Expression of RUNX1-ETO Rapidly Alters the Chromatin Landscape and Growth of Early Human Myeloid Precursor Cells. Cell reports, 31(8), 107691.

Cordonnier G, et al. (2020) CBF?-SMMHC Affects Genome-wide Polycomb Repressive Complex 1 Activity in Acute Myeloid Leukemia. Cell reports, 30(2), 299.

Luo H, et al. (2019) HOTTIP lncRNA Promotes Hematopoietic Stem Cell Self-Renewal Leading to AML-like Disease in Mice. Cancer cell, 36(6), 645.

Belver L, et al. (2019) GATA3-Controlled Nucleosome Eviction Drives MYC Enhancer Activity in T-cell Development and Leukemia. Cancer discovery, 9(12), 1774.

Ptasinska A, et al. (2019) RUNX1-ETO Depletion in t(8;21) AML Leads to C/EBP?- and AP-1-Mediated Alterations in Enhancer-Promoter Interaction. Cell reports, 28(12), 3022.

Yi G, et al. (2019) Chromatin-Based Classification of Genetically Heterogeneous AMLs into Two Distinct Subtypes with Diverse Stemness Phenotypes. Cell reports, 26(4), 1059.

Böiers C, et al. (2018) A Human IPS Model Implicates Embryonic B-Myeloid Fate Restriction as Developmental Susceptibility to B Acute Lymphoblastic Leukemia-Associated ETV6-RUNX1. Developmental cell, 44(3), 362.

Qu J, et al. (2018) Mutant p63 Affects Epidermal Cell Identity through Rewiring the Enhancer Landscape. Cell reports, 25(12), 3490.